No Data
No Data
Hoth Therapeutics Is Maintained at Buy by D. Boral Capital
Hoth Therapeutics Analyst Ratings
Express News | Hoth Therapeutics Partners With Ontargetx R&D to Advance Research for Cancer Fighting Ht-Kit Cancer Therapeutic
Hoth Therapeutics Partners With OnTargetx R&D to Advance Research for Cancer Fighting HT-KIT Cancer Therapeutic
Express News | Corrected-Hoth Therapeutics Shares Down 5% at $1.10 in Extended Trade Following Filing for Stock Offering (Deletes Erroneous Reference to Share Gain)
Express News | Hoth Therapeutics: Files for Common Stock Offering of up to $5 Mln - SEC Filing